

IMPLANTABLE BIO-RESORBABLE POLYMER

Field of the invention

The present invention relates to swellable and bio-resorbable cross-linked polymers
5 liable to be implanted in an individual and optionally to deliver drugs to the individual.

Technical background

There is a need, in the field of biomaterial implantation, for resorbable and swellable
particles. However, only incomplete solutions have been devised thus far.

10 Thus, gelatin sponges are biodegradable after implantation in tissues or injection in
cavities, ducts or vessels. They can be impregnated with physiological saline and/or contrast
media.

However, after their hydration they lose their shape and resistance. In addition, there
is a great variability in resorption speed, which is influenced by many factors such as nature,
15 homogeneity, size, enzymatic potential, and local inflammatory response. Moreover, since
the mass of resorbable gelatin may vary in large proportions, the resorption time of the plug
will consequently also take a variable time.

Another attempt consists of dextran starch microspheres (Spherex® from Pharmacia;
Embocept® from Pharmacept) which have been devised to provide for resorbable implants.
20 Indeed these dextran starch microspheres, which are non-toxic, are readily degradable and
are notably used to provide temporary vascular occlusion, mainly for the treatment of tumor
when co-administered with chemotherapeutic drugs.

However, dextran starch microspheres suffer from several limitations. First of all,
these microspheres are available only in small sizes, with diameters below 100 µm. Such a
25 small diameter does not allow targeted embolization, particularly for proximal occlusion.
Besides, resorption is fast, with a usual half life below 1 hour, and cannot be accurately
predicted since depends on the enzymatic capability to resorb a given microspheres volume.

Water-absorbent dry microspheres based on acrylic and PVA copolymers have also
been proposed as swellable implants (Osuga *et al.* (2002) *J Vasc Interv Radiol.* **13**:929-34).
30 In a commercial presentation (Quadrasphere®, Biosphere Medical), these microspheres are
under a dry form. For their use they are mixed with physiological saline, and/or iodinated
contrast media. Compared to their initial size, their final size after water uptake varies
according to the ionic charge of the medium (x2 or x4 in saline and contrast medium
respectively).

35 However the final size varies too much to allow for their controlled final volume after
implantation, which is a serious limitation for their use. Besides, these microspheres are not
resorbable.

It is therefore a goal of the present invention to solve the above problems.


Summary of the invention

The present invention arises from the unexpected finding, by the inventors, that the presence of neutral (meth)acrylates in a polymer cross-linked by bio-resorbable PLGA-, PEG- and/or PLA-based block copolymers can influence the rate of degradation of such a polymer while also allowing to control the swelling of the polymer. In addition, where the polymer is provided as a spherical particle, sphericity can be maintained even upon swelling.

Besides, it was further evidenced by the present inventors that in animal experiments performed in sheep shoulder joints, unlike microspheres of the prior art, polymer of the invention-based microspheres were quickly incorporated into the synovial tissue and that their residency time in synovium was at least of several weeks (1 month), making the microspheres of the invention suitable for delivering drug in the synovium for several weeks or months.

The present invention thus relates to a polymer obtained from the polymerization of:

(i) at least one monomer of formula (I)



wherein:


- K represents O-Z or NH-Z, Z representing $(\text{CR}_2\text{R}_3)_m\text{-CH}_3$, $(\text{CH}_2\text{-CH}_2\text{-O})_m\text{-H}$, $(\text{CH}_2\text{-CH}_2\text{-O})_m\text{-CH}_3$, $(\text{CH}_2)_m\text{-NR}_4\text{R}_5$ with m representing an integer from 1 to 30;
- R_1 , R_2 , R_3 , R_4 and R_5 independently represent H or a C1-C6 alkyl;

and

(ii) at least one bio-resorbable block copolymer cross-linker.

In an embodiment of the invention, the above-defined polymer is obtained from the polymerization of the at least one monomer, the at least one bio-resorbable block copolymer cross-linker, and at least one further monomer selected from the list comprising:


(i) a drug-carrying monomer of the following formula (III):



wherein:

- R_9 represents H or a C1-C6 alkyl;
- L represents a linker moiety having from 1 to 20 carbon atoms comprising a hydrolyzable function linked to the D group;
- the D group represents a drug or a prodrug; and

(ii) a charged, ionisable, hydrophilic, or hydrophobic monomer of the following formula (V):



wherein:

- R_{11} represents H or a C1-C6 alkyl;

- M represents a single bond or a linker moiety having from 1 to 20 carbon atoms;
- F represents a charged, ionisable,, hydrophilic, or hydrophobic group having 100 atoms at the most.


5 In another embodiment of the invention, the above-defined polymer is obtained from the polymerization of the at least one monomer, the at least one bio-resorbable block copolymer cross-linker, and the drug-carrying monomer.

10 In yet another embodiment of the invention, the above-defined polymer is obtained from the polymerization of the at least one monomer, the at least one bio-resorbable block copolymer cross-linker, and the at least one charged, ionisable, hydrophilic, or hydrophobic monomer.

15 These embodiments are advantageous in that where the polymer of the invention is polymerized from a drug-carrying monomer as defined above, the polymer can be used as a drug delivery system. Besides, where the polymer of the invention is polymerized from a charged, ionisable, hydrophilic, or hydrophobic monomer as defined above, the polymer may present with various physico-chemical surface characteristics enabling loading, *i.e.* non-covalently adsorbing, drugs to be delivered.

Thus, in a further embodiment of the invention, the above defined polymer is loaded with a drug or a prodrug.

20 In another embodiment of the invention, the above-defined polymer is obtained from the polymerization of the at least one monomer, the at least one block copolymer cross-linker, the at least one drug-carrying monomer, optionally the at least one charged, ionisable, hydrophilic, or hydrophobic monomer, and at least one hydrophilic monomer of the following formula (IV):



25 wherein:

- R_{10} represents H or a C1-C6 alkyl;
- Q represents a C1-C100 alkyl optionally substituted by at least one substituent selected from the group consisting of an hydroxyl, an oxo or an amino function.

30 The incorporation into the polymer of the invention of the above-defined hydrophilic monomer is advantageous in that it allows modulating the release of the drug by the polymer of the invention.

The present invention also relates to at least one polymer as defined above for use as a medicament.

35 The present invention also relates to a pharmaceutical composition comprising at least one polymer as defined above, in association with a pharmaceutically acceptable carrier.



Detailed description of the invention*Bio-resorbable block copolymer*

As intended herein, the expression "bio-resorbable" means that the block copolymer is degraded or cleaved when administered into a living organism, preferably a mammal, in particular a human, organism. As intended herein "bio-resorbable" indicates that the block copolymer may be hydrolyzed.

Preferably, the bio-resorbable block copolymer cross-linker as defined above is linear and presents $(\text{CH}_2=(\text{CR}_6))$ - groups at both its extremities, wherein R_6 independently represents H or a C1-C6 alkyl. Preferably also, the bio-resorbable block copolymer cross-linker is a diblock or a triblock copolymer.

It also preferred that the block of the bio-resorbable block copolymer cross-linker as defined above is selected from the groups consisting of polyethylene glycol (PEG), poly-lactic acid (also named poly-lactide) (PLA), poly-glycolic acid (also named poly-glycolide) (PGA) and poly-lactic-glycolic acid (PLGA).

As is well known to one of skill in the art, PEG, PLA and PGA may be represented as follows, n representing their degree of polymerization:



For PLGA which comprises both lactide and glycolide units, the degree of polymerization is the sum of the number of lactide and glycolide units.

More preferably, the bio-resorbable block copolymer cross-linker as defined above is of the following formula (II):



wherein:

- R_7 and R_8 independently represent H or a C1-C6 alkyl;

- X and Y independently represent PLA, PGA or PLGA;

- n, p, and k respectively represent the degree of polymerization of X, PEG, and Y, n and k independently being integers from 1 to 150, and p being an integer from 1 to 100;

- j represents 0 or 1.

Most preferably, the bio-resorbable block copolymer cross-linker as defined above is of a formula selected from the group consisting of:

$(\text{CH}_2=\text{CR}_7)\text{CO-PLA}_n\text{-PEG}_p\text{-PLA}_k\text{-CO-(CR}_8=\text{CH}_2)$,

$(\text{CH}_2=\text{CR}_7)\text{CO-PGA}_n\text{-PEG}_p\text{-PGA}_k\text{-CO-(CR}_8=\text{CH}_2)$,

5 $(\text{CH}_2=\text{CR}_7)\text{CO-PLGA}_n\text{-PEG}_p\text{-PLGA}_k\text{-CO-(CR}_8=\text{CH}_2)$,

$(\text{CH}_2=\text{CR}_7)\text{CO-PEG}_p\text{-PLA}_k\text{-CO-(CR}_8=\text{CH}_2)$,

$(\text{CH}_2=\text{CR}_7)\text{CO-PEG}_p\text{-PGA}_k\text{-CO-(CR}_8=\text{CH}_2)$, and

$(\text{CH}_2=\text{CR}_7)\text{CO-PEG}_p\text{-PLGA}_k\text{-CO-(CR}_8=\text{CH}_2)$;

wherein R_7 , R_8 , n , p and k are as defined above.


10

Polymer


As will be clear to one of skill in the art the polymer of the invention is a bio-resorbable (*i.e.* hydrolyzable) cross-linked polymer. In particular the polymer of the invention is constituted of at least one chain of polymerized monomers as defined above, which at least one chain is cross-linked by bio-resorbable block copolymer cross-linkers as defined above.

Advantageously, the polymer of the invention is swellable, *i.e.* has the capacity to absorb liquids, in particular water.

As will also be clear to one of skill in the art, and by way of example, the monomers of the invention may also be represented as follows:



Upon polymerization the monomers of the invention may then be represented as follows:



Preferably, the monomer of formula (I) as defined above is selected from the group consisting of sec-butyl acrylate, n-butyl acrylate, t-butyl acrylate, t-butyl methacrylate, methylmethacrylate, Ndimethyl-aminoethyl(methyl)acrylate, N,N-dimethylaminopropyl-(meth)acrylate, t-butylaminoethyl (methyl)acrylate, N,N-diethylaminoacrylate, acrylate terminated poly(ethylene oxide), methacrylate terminated poly(ethylene oxide), methoxy poly(ethylene oxide) methacrylate, butoxy poly(ethylene oxide) methacrylate, acrylate

25

30


terminated poly(ethylene glycol), methacrylate terminated poly(ethylene glycol), methoxy poly(ethylene glycol) methacrylate, butoxy poly(ethylene glycol) methacrylate.

Most preferably, the monomer of formula (I) as defined above is poly(ethylene glycol) methyl ether methacrylate.

It is also preferred that the hydrophilic monomer as defined above is selected from the group consisting of (meth)acrylamide, 2-hydroxyethyl (meth)acrylate, N-vinyl-2-pyrrolidone, butyl (meth)acrylate, acrylic acid, acrylic anhydride, N-trishydroxymethyl methacrylamide, glycerol mono(meth)acrylate, hydroxypropyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate.

Besides, it is preferred that F is selected from the group constituted of COOH, COO⁻, SO₃H, SO₃⁻, PO₄H₂, PO₄H⁻, PO₄²⁻, NR₁₁R₁₂, NR₁₁R₁₂R₁₃⁺, R₁₁, R₁₂ and R₁₃ independently representing H or a C1-C6 alkyl, a linear or branched alkyl group having from 1 to 20 carbon atoms, an aryl group having from 5 to 20 carbon atoms, a crown ether, and a cyclodextrin.

It is also preferred that L and M are of the following formula:



wherein T and T', identical or different, represent a C1-C6 alkyl chain optionally substituted by one or more hydroxyl, oxo, or amino group, U represents an hydrolysable function, such as an ester, amide, a disulfide, an amino-oxy or anhydride function, and q represents an integer from 0 to 2 for M and from 1 to 2 for L.

The polymer of the invention can be readily synthesized by numerous methods well-known to one of skill in the art. By way of example, the polymers of the invention can be obtained by suspension polymerization using either a direct or an inverse process as described below and in the Examples.

A direct suspension may proceed as follows: (a) stirring or agitating a mixture comprising (i) at least one monomer as defined above, and at least one bio-resorbable block copolymer cross-linker; (ii) a polymerization initiator present in amounts ranging from 0.1 to approximately 2 parts per weight per 100 parts by weight of the monomers; (iii) a surfactant in an amount no greater than about 5 parts by weight per 100 parts by weight of the monomers, preferably no greater than about 3 parts by weight and most preferably in the range of 0.5 to 1.5 parts by weight; and (iv) water to form an oil in water suspension; and (b) polymerizing the monomer(s) and the bio-resorbable block copolymer cross-linker.

An inverse suspension may proceed as follows: (a) stirring or agitating a mixture comprising: (i) at least one monomer as defined above, and at least one bio-resorbable block copolymer cross-linker; (ii) a polymerization initiator present in amounts ranging from 0.1 to approximately 2 parts per weight per 100 parts by weight of the monomers; (iii) a surfactant in an amount no greater than about 5 parts by weight per 100 parts by weight of the monomers, preferably no greater than about 3 parts by weight and most preferably in the

range of 0.5 to 1.5 parts by weight; and (iv) oil to form a water in oil suspension; and (b) polymerizing the monomers and the bio-resorbable block copolymer cross-linker.

Drug

As intended here the drug or prodrug as defined above can be of any type and intended for the prevention or treatment of any disease or impairment.

Preferably, where a covalent interaction with the polymer of the invention is sought, the drug should be such that it carries a reactive function, such as a carboxyl, a hydroxyl, a thiol or an amino group. For instance, the drug may comprise an acidic functionality (propionic acid, carboxylic group, or an acetic acid carboxylic group) with a lipophilic tail composed by aryl derivatives

As indicated above, in particular where the polymer of the invention is obtained from the polymerization at least one charged, ionisable, hydrophilic, or hydrophobic monomer, the drug may also be loaded onto the polymer, that is be adsorbed on the polymer by non-covalent interactions. No particular requirement are then imposed on the drug or prodrug to be loaded.

Loading may proceed by numerous methods well-known to one of skill in the art. For instance, the polymer in a dry form is made to swell in a solution containing a predetermined amount of the drug or the prodrug for 1h to 24h depending on the drug; the loaded polymer is then washed twice with a 0.9% (w/v) sodium chloride solution.

Besides, it is preferred that the drug as defined above is an anti-cancer drug or an NSAID.

Examples of suitable NSAIDs according to the invention encompass ibuprofen, ketoprofen, diclofenac, indomethacin or naproxen.

Examples of suitable anti-cancer drugs according to the invention encompass mitomycin, melphalan, methotrexate, raltirexed, gemcitabine, doxorubicine, or irinotecan.

Form of the polymer

Preferably, the polymer of the invention is in the form of a film, a foam, a particle, a lump, a thread, or a sponge, and most preferably is in the form of a spherical particle. The spherical particle is preferably a microsphere, *i.e.* has a diameter upon swelling (*i.e.* upon hydration), ranging from 1 to 5000 μm , more preferably ranging from 100 to 600 μm .

In order to swell, the polymer of the invention may absorb, preferably in a controlled way, liquids, such as water, in particular from solutions commonly used in embolization procedures, such as physiological saline, glucose solution, plasma, ionic or non ionic

iodinated contrast media, iron oxide based contrast media for magnetic resonance imaging, drug solutions, or any sterile apyrogen liquid that is injectable in the human or animal body. A defined and limited quantity of water is absorbed by the polymer of the invention, thereby enabling, where the polymer is a spherical particle, to anticipate the diameter upon swelling.

5

Pharmaceutical and therapeutical use of the polymer

Advantageously, the range which may be obtained for the polymer of the invention in the form of spherical particles makes it particularly suitable to block arterioles that are detectable by angiography and accessible by navigation to catheter and micro-catheters.

10 Besides, the ability of the polymer of the invention to absorb contrast media, such as barium sulphate, tungsten or tantalum, renders it particularly useful as a radio-opaque microsphere.

Advantageously also, resorption of the polymer of the invention depends on hydrolysis and not on an enzymatic mechanism. Resorption speed may thus be readily controlled by modulating the type and amount of bio-resorbable cross-linker and monomer as defined above.

15

Equally advantageous, resorption of the polymer of the invention may range from a few hours to a few weeks depending on the type and amount of bio-resorbable cross-linker and monomer as defined above. In addition, the polymer of the invention develops only a limited local inflammatory response upon implantation, since the degradation products of the polymer are non toxic and quickly eliminated.

20

Accordingly, the pharmaceutical composition as defined above is preferably for use as an implant, in particular for implantation into tissues, internal anatomical spaces, such as peritoneum and meningeal spaces, body cavities, ducts and vessels.

Besides, the pharmaceutical composition as defined above is preferably in an injectable form.

25

Preferably also, the pharmaceutical composition comprises the polymer of the invention in a dry form, such as a lyophilized form.

The pharmaceutical composition of the invention will be preferably used in the frame of embolization, in particular for uterine artery embolization (UAE), or for haemostasis. In embolization, the polymer of the invention need not comprise drugs or be loaded with drugs.

30

The pharmaceutical composition of the invention is also preferably used for treating cancer. In this case, treatment may occur by embolization, in particular by repeated embolization, and/or by delivery of anti-cancer drugs or prodrugs comprised in the polymer of the invention or loaded on the polymer of the invention.

Besides, the pharmaceutical composition of the invention may be preferably used for preventing or treating inflammation. In this case, it is preferred that the polymer of the invention comprises NSAIDs or be loaded by NSAIDs. In particular, the pharmaceutical

35

composition of the invention is particularly suited for preventing or treating inflammation associated with:

- joints cavities, tendons, cartilage, and bone defects;
- operative cavities after surgery of brain, in maxillar bone after teeth extraction, in
- 5 bone after resections, in liver or kidney after surgical tumor resection;
- muscles, in particular in cases of myositis or rupture;
- cerebrospinal fluid cavities in the central nervous system;
- joint surgery, arthroscopy, intrarticular lavage, menisectomy, osteotomy.

Examples

Example 1

5 1. Synthesis of the bio-resorbable cross-linker by the HEMA/PEGMA method:

1.1. PLA

- First step:

10 In a dry schlenk containing a magnetic stirring bar, lactide (2.2232 g ; 0.0154 mol) and hydroxyethyl methacrylate (0.75 mL; 0.0062 mol) were dissolved in 5ml of toluene under nitrogen. The reaction was initiated by introducing a toluene solution of Sn(Oct)₂ (8mg) into the above system. After 20h at 90°C, 5ml of chloroform was added to dilute the reaction mixture and the formed polymer was purified by precipitating in a large volume of petroleum ether. Yield 94%.

15 Characterization by ¹H NMR in CD₃COCD₃: 1.53 (m, CH₃, PLA), 1.91 (s, CH₃, methacrylate), 4.38 (m, CH₂, HEMA), 5.17 (m, CH, PLA), 5.65-6.10 (m, CH₂=C)

- Second step:

20 The polymer formed in the first step was further modified through the hydroxyl group at the end of PLA chain by reacting with methacryloyl chloride. The preformed polymer (1.07mmol of OH group, 1eq.) was dissolved in anhydrous CH₂Cl₂ (2.5ml) in a three necked flask equipped with magnetic stirrer and a dropping funnel. The content of the flask was cooled to 0°C and triethylamine (1.5eq.; 0.0016 mol) was added. The solution was stirred and then methacryloyl chloride (1.5eq.; 0.0016 mol) in CH₂Cl₂ (2.5ml) was added dropwise to the solution. The stirring was continued 1h at 0°C and then one night at room temperature.

25 The triethylamine salt was removed by filtration and the polymer was precipitated in a large volume of petroleum ether. Yield: 95%.

Characterization by ¹H NMR in CD₃COCD₃: 1.53 (m, CH₃, PLA), 1.91 (m, CH₃, methacrylate), 4.39 (m, CH₂, HEMA), 5.17 (m, CH, PLA), 5.65-6.16 (m, CH₂=C)

1.2. PGA

- First step:

30 In a dry schlenk containing a magnetic stirring bar, glycolide (0.6 g ; 0.005 mol) and hydroxyethyl methacrylate (21mg ; 0.0016 mol) were dissolved in 2ml of toluene under nitrogen. The reaction was initiated by introducing a toluene solution of Sn(Oct)₂ (5mg) into the above system. After 20h at 90°C, 5ml of chloroform was added to dilute the reaction mixture and the formed polymer was purified by precipitating in a large volume of petroleum ether. Yield 96%.

Characterization by ^1H NMR in CD_3COCD_3 : 1.91 (s, CH_3 , methacrylate), 4.38 (m, CH_2 , HEMA), 4.80 (m, CH_2 , PGA), 5.65-6.09 (s, $\text{CH}_2=\text{C}$)

- Second step:

The polymer formed in the first step was further modified through the hydroxyl group at the end of PGA chain by reacting with methacryloyl chloride. The preformed polymer (1 mmol of OH group, 1eq.) was dissolved in anhydrous CH_2Cl_2 (2 ml) in a three necked flask equipped with magnetic stirrer and a dropping funnel. The content of the flask was cooled to 0°C and triethylamine (1.5eq.; 0.0015 mol) was added. The solution was stirred and then methacryloyl chloride (1.5eq.; 0.0015 mol) in CH_2Cl_2 (2 ml) was added dropwise to the solution. The stirring was continued 1h at 0°C and then one night at room temperature. The triethylamine salt was removed by filtration and the polymer was precipitated in a large volume of petroleum ether. Yield: 50%.

Characterization by ^1H NMR in CD_3COCD_3 : 1.90 (m, CH_3 , methacrylates), 4.40 (m, CH_2 , HEMA), 4.81 (m, CH_2 , PGA), 5.65-6.16 (m, $\text{CH}_2=\text{C}$)

1.3. PLGA

- First step:

In a dry schlenk containing a magnetic stirring bar, lactide (1.18g; 8.23mmol), glycolide (0.95g; 8.23mmol) and hydroxyethyl methacrylate (0.53g; 4.1mmol) were dissolved in 5ml of toluene under nitrogen. The reaction was initiated by introducing a toluene solution of $\text{Sn}(\text{Oct})_2$ (8mg) into the above system. After 20h at 90°C , 5ml of chloroform was added to dilute the reaction mixture and the formed polymer was purified by precipitating in a large volume of petroleum ether.

Characterization by ^1H NMR in CD_3COCD_3 : 1.49 (m, CH_3 , PLA), 1.92 (s, CH_3 , methacrylate), 4.44 (m, CH_2 , HEMA), 4.83 (m, CH_2 , PGA), 5.25 (m, CH, PLA), 5.65-6.10 (s, $\text{CH}_2=\text{C}$)


- Second step:

The polymer formed in the first step was further modified through the hydroxyl group at the end of PLGA chain by reacting with methacryloyl chloride. In a typical reaction, the preformed polymer (8.23mmol of OH group, 1eq.) was dissolved in anhydrous CH_2Cl_2 (20ml) in a three necked flask equipped with magnetic stirrer and a dropping funnel. The content of the flask was cooled to 0°C and triethylamine (1.5eq.; 12.34mmol) was added. The solution was stirred and then methacryloyl chloride (1.5eq.; 12.34mmol) in CH_2Cl_2 (10ml) was added dropwise to the solution. The stirring was continued 1h at 0°C and then one night at room temperature. The triethylamine salt was removed by filtration and the polymer was precipitated in a large volume of petroleum ether.


Characterization by ^1H NMR in CD_3COCD_3 : 1.51 (m, CH_3 , PLA), 1.92 (s, CH_3 , methacrylates), 4.44 (m, CH_2 , HEMA), 4.83 (m, CH_2 , PGA), 5.25 (m, CH , PLA), 5.65-6.16 (m, $\text{CH}_2=\text{C}$)

5 Synthesis reactions are summarized in the following scheme:


Lactide



Glycolide



50/50 lactide/Glycolide



2. Synthesis of the bio-resorbable cross-linker by the PEG method:

2.1. PLA with TEG (PEG n=4)

10 - First step:

In a dry schlenk containing a magnetic stirring bar, the tetraethyleneglycol (0.139g ; 0.0007 mol) was reacted with d,l-lactide (1.032 g ; 0.0072 mol) for 20h at 115°C using stannous octoate as catalyst (5 mg) under nitrogen. Then, the polymer was dissolved in chloroform, precipitated in a large volume of petroleum ether.

Characterization by ^1H NMR in CD_3COCD_3 : 1.54 (m, CH_3 , PLA), 3.64 (m, CH_2 , PEG), 4.26 (m, CH_2 , PEG), 5.16 (m, CH, PLA)

- Second step:

5 The polymer formed in the first step was further modified through the hydroxyl groups at the end of PLA chNSAID by reacting with methacryloyl chloride. In a typical reaction, the preformed polymer was dissolved in anhydrous CH_2Cl_2 (10ml) in a three necked flask equipped with magnetic stirrer and a dropping funnel. The content of the flask was cooled to 0°C and triethylamine (1.5eq.; 0,0018 mol) was added. The solution was stirred and then methacryloyl chloride (1.5eq.; 0,0018 mol) in CH_2Cl_2 (5ml) was added dropwise to the
10 solution. The stirring was continued 1h at 0°C and then one night at room temperature. The triethylamine salt was removed by filtration and the polymer was precipitated in a large volume of petroleum ether.

Characterization by ^1H NMR in CD_3COCD_3 : 1.56 (m, CH_3 , PLA), 1.97 (m, CH_3 , methacrylate), 3.65 (m, CH_2 , PEG), 4.29 (m, CH_2 , PEG), 5.17 (m, CH, PLA), 5.64-6.20 (m,
15 $\text{CH}_2=\text{C}$).

2.2. PLGA with PEG 1500 (n=34)

- First step:

In a dry schlenk containing a magnetic stirring bar, the PEG1500 (2.25 g ; 0.0015
20 mol) was reacted with d,l-lactide (0.865 g ; 0.006 mol) and glycolide (0.697 g ; 0.006 mol) for 20h at 115°C using stannous octoate as catalyst (10 mg) under nitrogen. Then, the polymer was dissolved in chloroform, precipitated in a large volume of petroleum ether.

Characterization by ^1H NMR in CD_3COCD_3 : 1.55 (m, CH_3 , PLA), 3.64 (m, CH_2 , PEG), 4.25 (m, CH_2 , PEG), 4.84 (m, CH_2 , PGA), 5.20 (m, CH, PLA)



25 - Second step:

The polymer formed in the first step was further modified through the hydroxyl groups at the end of PLA chNSAID by reacting with methacryloyl chloride. In a typical reaction, the preformed polymer was dissolved in anhydrous CH_2Cl_2 (20ml) in a three necked flask equipped with magnetic stirrer and a dropping funnel. The content of the flask was cooled to
30 0°C and triethylamine (1.5eq.; 0.0045 mol) was added. The solution was stirred and then methacryloyl chloride (1.5eq.; 0.0045 mol) was added dropwise to the solution. The stirring was continued 1h at 0°C and then one night at room temperature. The triethylamine salt was removed by filtration and the polymer was precipitated in a large volume of petroleum ether/diethylether.



35 Characterization by ^1H NMR in CD_3COCD_3 : 1.56 (m, CH_3 , PLA), 1.94 (m, CH_3 , methacrylate), 3.63 (m, CH_2 , PEG), 4.29 (m, CH_2 , PEG), 4.86 (m, CH_2 , PGA), 5.23 (m, CH, PLA), 5.64-6.15 (m, $\text{CH}_2=\text{C}$)

Synthesis reactions are summarized in the following scheme:



Lactide



Glycolide



50/50 lactide/Glycolide



5

3. Synthesis of the microspheres by suspension polymerization:

3.1. With the PLA cross-linker from the HEMA/PEGMA method

10 A 0.5% of aqueous solution of 88% hydrolyzed polyvinylalcohol (90ml) was introduced into a 100ml reactor and allowed to stand under a nitrogen atmosphere for 15min. The monomer phase containing poly(ethylene glycol) methyl ether methacrylate (2.77g), PLA

cross-linker (0.7g) and 1wt% AIBN solubilized in 4.3ml of xylene was degassed by bubbling nitrogen through the solution for 15min. The monomer phase was added to the aqueous phase at 50°C and agitated by means of a propeller type stirrer at an appropriate velocity so as to obtain monomer droplets of desired diameter. The temperature was increased to 80°C and stirred for 5h. The mixture was filtered hot and washed with water and acetone. Then, beads were freeze dry. Size $390 \pm 100 \mu\text{m}$.


3.2. With the PLGA cross-linker from the HEMA/PEGMA method

A 0.75% of aqueous solution of 88% hydrolyzed polyvinylalcohol (220ml) was introduced into a 1000ml reactor and allowed to stand under a nitrogen atmosphere for 15min. The monomer phase containing poly(ethylene glycol) methyl ether methacrylate (5.9g; 19.6mmol), PLGA cross-linker (1g; 1.7mmol) and 1wt% AIBN solubilized in 10ml of toluene was degassed by bubbling nitrogen through the solution for 15min. The monomer phase was added to the aqueous phase at 50°C and agitated by means of a propeller type stirrer at an appropriate velocity so as to obtain monomer droplets of desired diameter. The temperature was increased to 80°C and stirred for 5h. The mixture was filtered hot and washed with water and acetone. Then, beads were freeze dry. Size = $246 \pm 150 \mu\text{m}$.

3.3. With the PLA cross-linker from PEG method

A 0.5% of aqueous solution of 88% hydrolyzed polyvinylalcohol (90ml) was introduced into a 100ml reactor and allowed to stand under a nitrogen atmosphere for 15min. The monomer phase containing poly(ethylene glycol) methyl ether methacrylate (3.252g), PLA cross-linker (0.36g) and 1wt% AIBN solubilized in 4.3ml of xylene was degassed by bubbling nitrogen through the solution for 15min. The monomer phase was added to the aqueous phase at 50°C and agitated by means of a propeller type stirrer at an appropriate velocity so as to obtain monomer droplets of desired diameter. The temperature was increased to 80°C and stirred for 5h. The mixture was filtered hot and washed with water and acetone. Then, beads were freeze dry. Size $450 \pm 100 \mu\text{m}$.

Synthesis reactions are summarized in the following scheme:



4. Degradation analysis:

50mg of dried microspheres were weighed and immersed in 10ml of PBS solution in individual vials kept at 37°C or 70°C. Samples were removed at designed times and immediately frozen to stop the degradation process. 6 samples were removed at each time point to gauge the variability in the degrading samples. The pH of each sample solution was measured and the mechanical properties of microspheres were determined using a compression method with a TAX-T2 apparatus. The results are presented in the following table.

Microspheres	Cross-linker	Size (μm)	Degradation time (days)
P1	HEMA-PGA (4%)	100-300	8
P2	HEMA-PLGA (4%)	300-500	35
P3	HEMA-PLGA (4%)	100-300	14
P4	HEMA-PLGA (6%)	100-300	28

5. Mechanical properties

Rigidity and elasticity are dominant parameters for injectability and repartition of embolization microsphere in a given vascular network.

As illustrated in the following table, the microspheres of the invention, upon swelling in an appropriate medium, such as saline, glucose solution, contrast media and mixtures of them, present mechanical performances of rigidity and elasticity which are adapted to the technical conditions of embolization and which compare to current commercialized microspheres: rigid to resist to the compression during the injection in syringes and catheters (microcatheters with an internal diameter mini 0.7 mm) and an elastic to regain its shape quickly after a deformation.

	Embosphere®	Embozene®	Hepasphere®	Microspheres of the invention (P2)
Young modulus (MPa)	3.79±0.6	1.93±0.8	2.6	3.64±0.87
Yield strength (MPa)	1.28±0.4	0.1±0.06	0.22±0.13	0.33±0.18

6- *In vivo*


Microspheres prepared as indicated above (P1, cross-linker HEMA-PGA, 200µm, 2g sterilised, size 100-300µm) were sterilized at 120°C 20 min and were suspended in a mixture of saline and iodinated contrast medium (250 mg in 4 ml) and injected by a 1mL syringe slowly in the renal flow with a microcatheter which tip was prealably positioned in the ostium of renal arteries in a pig. There was no blockade of the microcatheter and no resistance during manual injection of the microspheres suspension. At the end of embolisation an occlusion of the arteries in the embolised segment was observed on the angiographic control. Animal was sacrificed at 48H and kidneys sampled. Under pathologic microscopical examination, microspheres were visible in kidneys. They occluded completely the vessel lumens of several interlobular arteries. They looked as clear spheres. Some inflammatory cells were present on the microspheres. A partial resorption (~50%) is clearly visible (presence of vacuoles).

Example 2

1. Synthesis of ibuprofen monomers:

1.1. HEMA-iBu:

The following reaction was performed:




In a round bottom flask containing a magnetic stirring bar, ibuprofen (0.34g; 1.65mmol) and 4-Dimethylaminopyridine (0.01g; 0.09mmol) were solubilized in dry CH₂Cl₂ (4ml) under nitrogen atmosphere. Hydroxyethyl methacrylate (0.21g; 1.65mmol) and a mixture of dicyclohexylcarbodiimide (0.34g; 1.65mmol) dissolved in 2ml of dry CH₂Cl₂ were sequentially added at 0°C. After reacting 24h at 0°C, the mixture was filtrate and the crude product was purified on silica gel column (cyclohexane/ethyl acetate: 2/1).

Characterization by ¹H NMR in CD₃COCD₃: 0.88 (d, CH₃, isopropyl), 1.43 (d, CH₃-CH, ibuprofen), 1.85 (m, CH₃, methacrylate + CH-iPr, ibuprofen), 2.44 (d, CH₂-phenyl, ibuprofen), 3.75 (q, phenyl-CH-COO-, ibuprofen), 4.31 (m, CH₂, HEMA), 5.59-5.98 (m, CH₂=C), 7.16 (dd, C₆H₄)

1.2. GMA-iBu

The following reaction was performed:




Glycidyl methacrylate (1.348 g ; 9.5 mmol), ibuprofen (1.955 g; 9.5 mmol), hydroquinone (0.2g) and pyridine (2ml) were dissolved in 5ml of DMF. The mixture was shaken under vacuum at 40°C for 6h. Then, the mixture was cooled and poured in aqueous saturated NaHCO₃ solution (20ml). The organic phase was extracted three times by ethyl acetate, washed with saturated NaCl solution, dried on MgSO₄ and the solvent evaporated under reduced pressure. The residue was purified by chromatography (ethyl acetate / cyclohexane: 1/5). Yield : 40%.

Characterization by ¹H NMR in CDCl₃: 0.89 (d, CH₃, isopropyl), 1.51 (d, CH₃-CH, ibuprofen), 1.85 (m, CH-iPr, ibuprofen), 1.94 (s, CH₃, methacrylate), 2.45 (d, CH₂-phenyl, ibuprofen), 3.75 (q, phenyl-CH-COO-, ibuprofen), 4.08-4.19 (m, CH₂-CH(OH)-CH₂), 5.60-6.12 (m, CH₂=C), 7.16 (dd, C₆H₄)

2. Synthesis of microspheres by suspension polymerization:

The following reaction was performed:



A 0.75% of aqueous solution of 88% hydrolyzed polyvinylalcohol (220ml) was introduced into a 1000ml reactor and allowed to stand under a nitrogen atmosphere for 15min. The monomer phase containing HEMA-iBu (1.6g; 5mmol), poly(ethylene glycol) methyl ether methacrylate (5.9g; 19.6mmol), PLGA cross-linker (1g; 1.7mmol) and 1wt% AIBN solubilized in 10ml of toluene was degassed by bubbling nitrogen through the solution for 15min. The monomer phase was added to the aqueous phase at 50°C and agitated by means of a propeller type stirrer at an appropriate velocity so as to obtain monomer droplets of desired diameter. The temperature was increased to 80°C and stirred for 5h. The mixture was filtered hot and washed with water and acetone. Then, beads were freeze dry.

The characteristics of the prepared microspheres are summarized in the following table:

Microspheres	Cross-linker	iBu	size
P5	HEMA-PLGA(8%)	20	40-100
P6	TEG-PLGA (5%)	20	40-100
P7	TEG-PLGA (3%)	43	40-100

3. *In vitro* release of ibuprofen:

220mg of ibuprofen loaded microspheres (P6) was suspended in a vial containing 30ml of PBS (pH7.4). The vial was incubated at 37 °C with constant shaking. At time intervals, the vial was centrifugated for 10s and sample (100µl) from the releasing medium

was withdrawn for UV and HPLC analyses. The withdraw volume was replaced with fresh buffer followed by resuspending before continuing incubation.

Microspheres	% iBu released		
	Day30	Day60	Day90
P6 TEG-PLGA (5%)-20% iBu	6	8	14
P7 TEG-PLGA (3%) 43% iBu	1	1.5	2

4. *In vivo* : intra-articular injection of microspheres (P8+P9) in sheep joint shoulder

5

An implantation study of microspheres was performed in sheep shoulder joints (gleno-humeral joint). Two species of microspheres (40 – 100 μ m) were injected: resorbable microspheres (P8-TEG-PLGA 6% with PEGMMA 300) and non-resorbable microspheres (P9-PEGdiacrylate (M=575) 6% with PEGMMA 300) which are inflammatory. One week and one month after intra-articular injection, the synovial inflammatory reaction induced by resorbable microspheres was compared to inflammation triggered with non-resorbable microspheres.

10

In sterile conditions, depyrogenised and sterilized microspheres were suspended in physiological serum. Then, 1 mL sterile syringes were loaded with a volume of microsphere pellet corresponding to 50 mg of dry microspheres. Under general anesthesia, synovial fluid ponction was performed on the right shoulder from 6 adult sheep (3 – 4 years old), then the syringe containing microspheres was placed on the needle located in the joint cavity. Microspheres were injected slowly in the articular space.

15

After one and four weeks, animals (3 per group) were sacrificed and synovial fluid from shoulder was recovered. The whole shoulder joints were removed and fixed in formalin 10 %. Then, synovial tissues were cut and stained with haematoxylin/eosin for microscopic observation.

20

In the joint, the injected microspheres were located either into the synovial fluid or in the synovial lining of joint. Migration of microspheres to the synovial lining of capsule did not induce cell proliferation. The inflammatory response of synovial tissue to the resorbable microspheres was compared to inflammation induced by non-resorbable microspheres. Cells surrounding the microspheres incorporated into the synovial lining were numbered (0.1 mm² field). After one week, 253 $\pm$ 57 cells were observed around non-resorbable microspheres, whereas only 83 $\pm$ 15 cells were observed around resorbable microspheres ($p < 0.0001$). One month after injection, 172 $\pm$ 34 cells surround non-resorbable microspheres compared to 98 $\pm$ 36 cells for resorbable microspheres ($p = 0.0005$). The absence of giant cells around the resorbable microspheres confirmed the low level of inflammation induce in joint

25

30

with these resorbable particles, by opposition to what was observed on non-resorbable microspheres.

In the synovial fluid, at one month after injection, the biodegradable microspheres have disappeared in profit to flat fragments indicating that microsphere resorption had occurred. Concerning the microspheres located within the synovial membrane, they were highly distorted and vacuolized.

Histology showed that resorbable microspheres migrate into the synovial lining and these immobilized microspheres are well tolerated by the synovial tissues of shoulder joint without significant cell proliferation. Furthermore, resorption of microspheres did not induce an inflammatory response.

Example 3

1. Microspheres with a HEMA-PLGA cross-linker and a hydroxyl function:

A 0.5% of aqueous solution of 88% hydrolyzed polyvinylalcohol (300ml) was introduced into a 500ml reactor and allowed to stand under a nitrogen atmosphere for 15min. The monomer phase containing poly(ethylene glycol)methacrylate (9.45 g ; 17.97 mmol), poly(ethylene glycol) methyl ether methacrylate (5.47g ; 18.23 mmol), PLGA cross-linker (0.9 g ; 1.52 mmol) and 1wt% AIBN solubilized in 14ml of toluene was degassed by bubbling nitrogen through the solution for 15min. The monomer phase was added to the aqueous phase at 50°C and agitated by means of a propeller type stirrer at an appropriate velocity so as to obtain monomer droplets of desired diameter. The temperature was increased to 80°C and stirred for 5h. The mixture was filtered hot and washed with water and acetone. Then, beads were freeze dry.

2. Microspheres with a HEMA-PLGA cross-linker and an acid function:

A 0.5% of aqueous solution of 88% hydrolyzed polyvinylalcohol (300ml) was introduced into a 500ml reactor and allowed to stand under a nitrogen atmosphere for 15min. The monomer phase containing methacrylic acid (2.33g ; 27.07 mmol), polyethylene glycol methacrylate (8.05g ; 26.83 mmol), PLGA cross-linker (1.32 g ; 2.24 mmol) and 1wt% AIBN solubilized in 14ml of toluene was degassed by bubbling nitrogen through the solution for 15min. The monomer phase was added to the aqueous phase at 50°C and agitated by

means of a propeller type stirrer at an appropriate velocity so as to obtain monomer droplets of desired diameter. The temperature was increased to 80°C and stirred for 5h. The mixture was filtered hot and washed with water and acetone. Then, beads were freeze dry.

5 **3. Microspheres with PEG1500-PLGA cross-linker and acid function:**

10 A solution of Span80® (1%) dissolved in 200ml of cyclohexane was introduced into a 2000ml reactor and allowed to stand under a nitrogen atmosphere for 15min. The monomer phase containing acrylic acid (2.4g ; 33.3 mmol), N,N-diméthylacrylamide (4g ; 40.35 mmol),
15 PEG-PLGA cross-linker (3 g) and 1wt% ammonium peroxyde disulfate solubilized in 28ml of water was degassed by bubbling nitrogen through the solution for 15min. The monomer phase was added to the organic phase at ambient temperature and agitated by means of a propeller type stirrer at an appropriate velocity so as to obtain monomer droplets of desired diameter. The temperature was increased to 70°C and stirred for 2h. The mixture was filtered hot and washed with water and acetone. Then, beads were freeze dry.

Claims

1. A polymer obtained from the polymerization of:

(i) at least one monomer of formula (I)



wherein:

- K represents O-Z or NH-Z, Z representing $(\text{CR}_2\text{R}_3)_m\text{-CH}_3$, $(\text{CH}_2\text{-CH}_2\text{-O})_m\text{-H}$, $(\text{CH}_2\text{-CH}_2\text{-O})_m\text{-CH}_3$, $(\text{CH}_2)_m\text{-NR}_4\text{R}_5$ with m representing an integer from 1 to 30;
- R_1 , R_2 , R_3 , R_4 and R_5 independently represent H or a C1-C6 alkyl;

10 and

(ii) at least one bio-resorbable block copolymer cross-linker.

2. The polymer according to claim 1, wherein the bio-resorbable block copolymer cross-linker is linear and presents $(\text{CH}_2=(\text{CR}_6))\text{-}$ groups at both its extremities, wherein R_6 independently

15 represents H or a C1-C6 alkyl.

3. The polymer according to claim 1 or 2, wherein the block of the bio-resorbable block copolymer cross-linker is selected from the groups consisting of polyethylene glycol (PEG), poly-lactic acid (PLA), poly-glycolic acid (PGA) and poly-lactic-glycolic acid (PLGA).

20

4. The polymer according to any of claims 1 to 3, wherein the bio-resorbable block copolymer cross-linker is of the following formula (II):



wherein:

25 - R_7 and R_8 independently represent H or a C1-C6 alkyl;



- X and Y independently represent PLA, PGA or PLGA;

- n, p, and k respectively represent the degree of polymerization of X, PEG, and Y, n and k independently being integers from 1 to 150, and p being an integer from 1 to 100;

- j represents 0 or 1.

30

5. The polymer according to any of claims 1 to 4, wherein the bio-resorbable block copolymer cross-linker is of a formula selected from the group consisting of:



$(\text{CH}_2=\text{CR}_7)\text{CO-PEG}_p\text{-PLGA}_k\text{-CO-(CR}_8=\text{CH}_2)$;


wherein R_7 , R_8 , n , p and k are as defined in claim 4.

5 6. The polymer according to any of claims 1 to 5, wherein the monomer of formula (I) is selected from the group consisting of sec-butyl acrylate, n-butyl acrylate, t-butyl acrylate, t-butyl methacrylate, methylmethacrylate, Ndimethyl-aminoethyl(methyl)acrylate, N,N-dimethylaminopropyl-(meth)acrylate, t-butylaminoethyl (methyl)acrylate, N,N-diethylaminoacrylate, acrylate terminated poly(ethylene oxide), methacrylate terminated poly(ethylene oxide), methoxy poly(ethylene oxide) methacrylate, butoxy poly(ethylene oxide) methacrylate, acrylate terminated poly(ethylene glycol), methacrylate terminated poly(ethylene glycol), methoxy poly(ethylene glycol) methacrylate, butoxy poly(ethylene glycol) methacrylate.

15 7. The polymer according to any of claims 1 to 6, wherein the monomer of formula (I) is poly(ethylene glycol) methyl ether methacrylate.

8. The polymer according to any of claims 1 to 7, obtained from the polymerization of the at least one monomer, the at least one bio-resorbable block copolymer cross-linker, and at least one further monomer selected from the list comprising:


20 (i) a drug-carrying monomer of the following formula (III):



wherein:

- R_9 represents H or a C1-C6 alkyl;
- L represents a linker moiety having from 1 to 20 carbon atoms comprising a hydrolyzable function linked to the D group;
- the D group represents a drug or a prodrug; and

(ii) a charged, ionisable, hydrophilic, or hydrophobic monomer of the following formula (V):




wherein:

- 30 - R_{11} represents H or a C1-C6 alkyl;
- M represents a single bond or a linker moiety having from 1 to 20 carbon atoms;
- F represents a charged, ionisable, hydrophilic, or hydrophobic group having 100 atoms at the most.

35 9. The polymer according to claim 8, obtained from the polymerization of the at least one monomer, the at least one bio-resorbable block copolymer cross-linker, and the drug-carrying monomer.

10. The polymer according to claim 8 or 9, obtained from the polymerization of the at least one monomer, the at least one bio-resorbable block copolymer cross-linker, the at least one drug-carrying monomer, optionally the at least one charged, ionisable, hydrophilic, or hydrophobic monomer, and at least one hydrophilic monomer of the following formula (IV):



wherein:

- R_{10} represents H or a C1-C6 alkyl;

- Q represents a C1-C100 alkyl optionally substituted by at least one substituent selected from the group consisting of an hydroxyl, an oxo or an amino function.

11. The polymer according to claim 10, wherein the hydrophilic monomer is selected from the group consisting of (meth)acrylamide, 2-hydroxyethyl (meth)acrylate, N-vinyl-2-pyrrolidone, butyl (meth)acrylate, acrylic acid, acrylic anhydride, N-trishydroxymethyl methacrylamide, glycerol mono(meth)acrylate, hydroxypropyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate.

12. The polymer according to claim 8, obtained from the polymerization of the at least one monomer, the at least one block copolymer cross-linker, and the at least one charged, ionisable, hydrophilic, or hydrophobic monomer.

13. The polymer according to any of claims 8, and 10 to 12, wherein F is selected from the group constituted of COOH , COO^- , SO_3H , SO_3^- , PO_4H_2 , PO_4H^- , PO_4^{2-} , $\text{NR}_{11}\text{R}_{12}$, $\text{NR}_{11}\text{R}_{12}\text{R}_{13}^+$, R_{11} , R_{12} and R_{13} independently representing H or a C1-C6 alkyl, a linear or branched alkyl group having from 1 to 20 carbon atoms, an aryl group having from 5 to 20 carbon atoms, a crown ether, and a cyclodextrin.

14. The polymer according to any of claims 8, and 10 to 12, loaded with a drug or a prodrug.

15. The polymer according to any of claim 8 to 11 and 14, wherein the drug or the prodrug is an anti-cancer drug.

16. The polymer according to any of claims 8 to 11 and 14, wherein the drug or the prodrug is an NSAID.

17. The polymer according to any of claims 1 to 16, which is in the form of a film, a foam, a particle, in particular a spherical particle, a lump, a thread, or a sponge.

18. A pharmaceutical composition comprising at least one polymer according to any of claim 1 to 17, in association with a pharmaceutically acceptable carrier.

19. The pharmaceutical composition according to claim 18, for use as an implant.

5

20. The pharmaceutical composition according to claim 18 or 19, in an injectable form.

21. The pharmaceutical composition according to any of claims 18 to 20, for implantation into tissues, internal anatomical spaces, body cavities, ducts and vessels.

10

22. The pharmaceutical composition according to any of claims 18 to 21, for treating inflammation or cancer.